New Trends in Laboratory Medicine

New Trends in Laboratory Medicine

Tuesday, February 4, 2025 11:00 AM to 1:30 PM · 2 hr. 30 min. (Asia/Dubai)
Room Oman

Information

We are greatly honoured to introduce a distinguished group of speakers, all of whom are esteemed authorities in the domain of laboratory medicine. They will share with us their valuable knowledge and insights on therapeutic monitoring of immunosuppressive drugs, the role of artificial intelligence in the diagnosis of prostate markers, the importance of laboratory certification and the CAP certification process, clinical information in validating clinical chemistry tests, interference in immunoassays, etc. Let's share this feast of laboratory medicine!

Learning objectives

To understand the application of therapeutic monitoring of immunosuppressive drugs and its clinical implications

To understand the role of artificial intelligence in the diagnosis of prostate markers and their characteristics

To recognize the importance of laboratory certification, including the CAP certification process

To appreciate the significance of clinical information in validating clinical chemistry tests, including test methodologies, interferences, and result validation

To learn strategies for minimizing interferences in immunoassays, enhancing diagnostic accuracy and reliability in various healthcare settings

This is an ATTEND IN PERSON session, taking place at Oman Room DWTC. If you have any questions about the session, please send an email to Customer Success Team.IMCustomerSuccess@informa.com

Location
Room Oman
Session Type
Non-CME
Conference Track
Workshop
Snibe Co., Ltd.Z5.C30Shenzhen New Industries Biomedical Engineering Co., Ltd (briefed as Snibe) is a leading global in-vitro diagnostic biomedical enterprise that has been focusing on the Chemiluminescence immunoassay (CLIA) field for over 29 years, and has become the first CLIA manufacturer in China who got FDA cleared in 2017. Snibe offers customized diagnostic solutions to laboratories in more than 155 countries and regions. Over 30,000 units of Snibe's CLIA analyzers have been installed in hospitals and labs worldwide, including many top global chain labs. Over 29 years, Snibe has established 4 core R&D centers, including reagent, instrument, magnetic microbead, and reagent raw material, laying a solid foundation for developing the widest range of CLIA analyzers and test menus. Currently, Snibe's business segments cover various sections of clinical laboratory diagnosis, including CLIA, Biochemistry, Molecular Diagnostics, and Hemostasis, comprehensively meeting different diagnostic needs. Our Mission is "Creating value for human health through continuous innovation".

Speakers

Dr Dheepa Manoharan
Dr Dheepa Manoharan
Medical Director, QLABS Clinical Laboratory Member, ISHAM, AACC, SYCL Stewardship from British Society for Antimicrobial Chemotherapy (BSAC)QLABS Clinical Laboratory
Professor Adel Ahmed Elazab Elged
Professor Adel Ahmed Elazab Elged
"* Professor of Clinical Pathology, Ain Shams University, Cairo, Egypt. * Dean of Faculty of Applied Health Sciences, Galala University, Suez, Egypt. * Core Lab Manager, Royal Lab, Cairo, Egypt"Core Lab Manager, Royal Lab
Dr Meenakshi Jain
Dr Meenakshi Jain
Specialist Clinical Pathologist, Laboratory DirectorUnilabs Middel East,Dubai,UAE
Professor Harald Renz
Professor Harald Renz
Professor and Director of Institute of Laboratory Medicine and Pathobiochemistry, Molecular DiagnosticsUniversity Hospital Gießen and Marburg Institute of Laboratory Medicine
Dr George Karim Sahyoun
Dr George Karim Sahyoun
Chief Operations Officer of MedLabs Consultancy Group_x000D_ Chief Scientific Officer and Director of the Medlabs Reference Laboratory Medlabs, JordanMedlabs Reference Laboratory Medlabs, Jordan
Dr Nada Syazana Zulkufli
Dr Nada Syazana Zulkufli
Chemical Pathologist & Core Laboratory Director, Precision Diagnostics, Malaysia_x000D_ MBBS (Monash), MRCPI (Ireland), MPath (Chemical) (UM), AM (Mal)Precision Diagnostics

Log in